Clinical Trials Browser

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT02153931 2019-01-31

Internet Support Group for Parents of a Child With Neurofibromatosis Type 1

Completed

33 enrolled

CNS

Anxiety Disorders, Depression, Neurofibromatosis 1

NCT00076102 2018-04-23

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

Phase 2 Completed

36 enrolled 13 charts

CNS

Neurofibromatosis 1, Nerve Sheath Neoplasms, Neurofibroma, Plexiform

NCT00021541 2018-04-17

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Phase 2 Completed

62 enrolled 13 charts

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT00326872 2017-08-18

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Phase 2 Terminated

26 enrolled 8 charts

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT00053937 2015-04-30

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

Phase 1 Completed

CNSOther neoplasm

Neurofibromatosis 1, Precancerous Conditions, Neurofibroma, Plexiform

Clinical Trials

Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)

Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Natural History Study of Patients With Neurofibromatosis Type I

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)

Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Eligibility Screening for a NCI Pediatric Oncology Branch Research Study

Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Internet Support Group for Parents of a Child With Neurofibromatosis Type 1

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas